UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

The New England journal of medicine, 2018-12, Vol.379 (23), p.2220-2229

2018

Volltextzugriff (PDF)

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-08, Vol.29 (22), p.2965-2971

2011

Volltextzugriff (PDF)

Density of tumor-infiltrating NK and Treg cells is associated with 5 years progression-free and overall survival in resected lung adenocarcinoma

Lung cancer (Amsterdam, Netherlands), 2024-06, Vol.192, p.107824-107824, Article 107824

2024

Volltextzugriff (PDF)

Ceritinib in second and further lines of therapy in advanced ALK mutant adenocarcinoma

Journal of thoracic disease, 2016-07, Vol.8 (7), p.E584-E585

Losonczy, György

2016

Volltextzugriff (PDF)

Dysregulation of the endothelial nitric oxide pathway is associated with airway inflammation in COPD

Respiratory research, 2019-07, Vol.20 (1), p.156-10, Article 156

2019

Volltextzugriff (PDF)

The link between the sphingolipid rheostat and obstructive sleep apnea

Scientific reports, 2023-05, Vol.13 (1), p.7675-7675, Article 7675

2023

Volltextzugriff (PDF)

Blood eosinophils on hospital admission for COPD exacerbation do not predict the recurrence of moderate and severe relapses

ERJ open research, 2021-01, Vol.7 (1), p.543

2021

Volltextzugriff (PDF)

Súlyos hypoxaemia légszomj nélkül COVID–19-pneumoniában

Orvosi hetilap, 2021-03, Vol.162 (10), p.362-365

2021

Volltextzugriff (PDF)

Central and peripheral airway nitric oxide in patients with stable and exacerbated chronic obstructive pulmonary disease

Journal of breath research, 2018-05, Vol.12 (3), p.036017-036017

2018

Volltextzugriff (PDF)

Jobb kamrai adaptáció pulmonalis artériás hypertoniában

Orvosi hetilap, 2021-09, Vol.162 (37), p.1485-1493

2021

Volltextzugriff (PDF)

Circulating heat shock protein 70 (HSPA1A) in normal and pathological pregnancies

Cell stress & chaperones, 2010-05, Vol.15 (3), p.237-247

2010

Volltextzugriff (PDF)

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

JTO clinical and research reports, 2022-06, Vol.3 (6), p.100330-100330, Article 100330

2022

Volltextzugriff (PDF)

Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation

BMC pulmonary medicine, 2011-07, Vol.11 (1), p.40-40, Article 40

2011

Volltextzugriff (PDF)

Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy

PloS one, 2013-04, Vol.8 (4), p.e60697-e60697

2013

Volltextzugriff (PDF)

Airway dynamics in COPD patients by within-breath impedance tracking: effects of continuous positive airway pressure

The European respiratory journal, 2017-02, Vol.49 (2), p.1601270-1601270

2017

Volltextzugriff (PDF)

P192: Endothelial Dysfunction, Arterial Stiffness in Lung Transplanted Individuals

Artery research, 2017-12, Vol.20 (1), p.109-109

2017

Volltextzugriff (PDF)

Galectin-9 in Allergic Airway Inflammation and Hyper-Responsiveness in Mice

International archives of allergy and immunology, 2010-01, Vol.151 (4), p.308-317

2010

Volltextzugriff (PDF)

Human CD40 ligand–expressing type 3 innate lymphoid cells induce IL-10–producing immature transitional regulatory B cells

Journal of allergy and clinical immunology, 2018-07, Vol.142 (1), p.178-194.e11

2018

Volltextzugriff (PDF)

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

Lung cancer (Amsterdam, Netherlands), 2020-11, Vol.149, p.46-52

2020

Volltextzugriff (PDF)

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study

Lung cancer (Amsterdam, Netherlands), 2024-10, Vol.196, p.107924, Article 107924

2024

Volltextzugriff (PDF)

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

The Lancet (British edition), 2019-11, Vol.394 (10212), p.1929-1939

2019

Volltextzugriff (PDF)

Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide

Lung cancer (Amsterdam, Netherlands), 2023-12, Vol.186, p.107418-107418, Article 107418

2023

Volltextzugriff (PDF)

1 – 25 von 199

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieAmerican Journal Of Physiology. Heart And Circulatory Physiology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(188)
Mit Volltextzugriff
(158)

Publikationsform

Artikel
(199)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

Density of tumor-infiltrating NK and Treg cells is associated with 5 years progression-free and overall survival in resected lung adenocarcinoma

Ceritinib in second and further lines of therapy in advanced ALK mutant adenocarcinoma

Dysregulation of the endothelial nitric oxide pathway is associated with airway inflammation in COPD

The link between the sphingolipid rheostat and obstructive sleep apnea

Blood eosinophils on hospital admission for COPD exacerbation do not predict the recurrence of moderate and severe relapses

Súlyos hypoxaemia légszomj nélkül COVID–19-pneumoniában

Central and peripheral airway nitric oxide in patients with stable and exacerbated chronic obstructive pulmonary disease

Jobb kamrai adaptáció pulmonalis artériás hypertoniában

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Circulating heat shock protein 70 (HSPA1A) in normal and pathological pregnancies

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation

Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

Airway dynamics in COPD patients by within-breath impedance tracking: effects of continuous positive airway pressure

P192: Endothelial Dysfunction, Arterial Stiffness in Lung Transplanted Individuals

Galectin-9 in Allergic Airway Inflammation and Hyper-Responsiveness in Mice

Human CD40 ligand–expressing type 3 innate lymphoid cells induce IL-10–producing immature transitional regulatory B cells

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide

Aktive Filter

Suchergebnisse filtern